BR0209290A - Tratamento de demência e doenças neurodegenerativas com doses intermediárias de antagonistas de lhrh - Google Patents

Tratamento de demência e doenças neurodegenerativas com doses intermediárias de antagonistas de lhrh

Info

Publication number
BR0209290A
BR0209290A BR0209290-5A BR0209290A BR0209290A BR 0209290 A BR0209290 A BR 0209290A BR 0209290 A BR0209290 A BR 0209290A BR 0209290 A BR0209290 A BR 0209290A
Authority
BR
Brazil
Prior art keywords
dementia
treatment
neurodegenerative diseases
lhrh antagonists
intermediate doses
Prior art date
Application number
BR0209290-5A
Other languages
English (en)
Portuguese (pt)
Inventor
Juergen Engel
Rainer Voegeli
Original Assignee
Zentaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris Gmbh filed Critical Zentaris Gmbh
Publication of BR0209290A publication Critical patent/BR0209290A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10Peptides having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/09Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
BR0209290-5A 2001-04-30 2002-04-27 Tratamento de demência e doenças neurodegenerativas com doses intermediárias de antagonistas de lhrh BR0209290A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28743401P 2001-04-30 2001-04-30
PCT/EP2002/004677 WO2002102401A1 (en) 2001-04-30 2002-04-27 Treatment of dementia and neurodegenerative diseases with intermediate doses of lhrh antagonists

Publications (1)

Publication Number Publication Date
BR0209290A true BR0209290A (pt) 2004-07-13

Family

ID=23102886

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0209290-5A BR0209290A (pt) 2001-04-30 2002-04-27 Tratamento de demência e doenças neurodegenerativas com doses intermediárias de antagonistas de lhrh

Country Status (27)

Country Link
US (1) US7288517B2 (enExample)
EP (1) EP1392348B1 (enExample)
JP (1) JP2004529207A (enExample)
KR (1) KR20040000446A (enExample)
CN (1) CN1317030C (enExample)
AT (1) ATE400287T1 (enExample)
AU (1) AU2002310788B2 (enExample)
BG (1) BG108339A (enExample)
BR (1) BR0209290A (enExample)
CA (1) CA2444876A1 (enExample)
CZ (1) CZ20033167A3 (enExample)
DE (1) DE60227507D1 (enExample)
DK (1) DK1392348T3 (enExample)
ES (1) ES2307760T3 (enExample)
HU (1) HUP0400067A2 (enExample)
IL (1) IL156777A0 (enExample)
MX (1) MXPA03008666A (enExample)
NO (1) NO20034322D0 (enExample)
NZ (1) NZ544417A (enExample)
PL (1) PL362319A1 (enExample)
PT (1) PT1392348E (enExample)
RU (1) RU2319501C2 (enExample)
SI (1) SI1392348T1 (enExample)
SK (1) SK14512003A3 (enExample)
UA (1) UA80679C2 (enExample)
WO (1) WO2002102401A1 (enExample)
ZA (1) ZA200305326B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828415B2 (en) * 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
US20020077327A1 (en) * 1999-09-23 2002-06-20 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
CN1186326C (zh) * 2000-07-05 2005-01-26 山之内制药株式会社 丙-1,3-二酮衍生物
DE10137174A1 (de) * 2001-07-31 2003-02-13 Zentaris Ag Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität
UA83928C2 (ru) 2004-06-04 2008-08-26 Астеллас Фарма Инк. Производное пропан-1,3-диона или его соль
US20080171736A1 (en) * 2004-12-23 2008-07-17 Gregory Christopher W Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists
CN101087618A (zh) * 2004-12-23 2007-12-12 航行药物公司 醋酸亮丙瑞林和乙酰胆碱酯酶抑制剂或nmda受体抑制剂在阿尔茨海默氏病治疗中的应用
EP1864976B1 (en) 2005-03-31 2012-10-10 Astellas Pharma Inc. Propane-1,3-dion derivative or salt thereof
EP2535336A1 (en) 2006-10-21 2012-12-19 Abbott GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors
WO2009033781A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
WO2009040006A1 (en) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Spantide for therapeutic uses
EP2095818A1 (en) * 2008-02-29 2009-09-02 AEterna Zentaris GmbH Use of LHRH antagonists at non-castrating doses
EP2307040B1 (en) * 2008-05-29 2015-09-09 Isr Immune System Regulation Ab Use of gnrh and sex hormones for treating viral disease, in particular hiv/aids
EP2621914B1 (en) 2010-09-27 2016-12-28 Abbott GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
US9090592B2 (en) 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
EP3560555A1 (en) 2018-04-26 2019-10-30 LifeArc A composition for treating one or more estrogen related diseases
WO2025155903A1 (en) * 2024-01-19 2025-07-24 Temple University-Of The Commonwealth System Of Higher Education Compositions of antioxidant translation modulators for treating neurodegenerative disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3135743A (en) * 1960-06-29 1964-06-02 Sterling Drug Inc Steroido[2. 3-d]isoxazoles and preparation thereof
JP2000511532A (ja) 1996-05-20 2000-09-05 メルク エンド カンパニー インコーポレーテッド 性腺刺激ホルモン放出ホルモンのアンタゴニスト
DE19911771B4 (de) * 1999-03-17 2006-03-30 Zentaris Gmbh LHRH-Antagonist, Verfahren zu seiner Herstellung und seiner Verwendung
MXPA01011634A (es) 1999-05-14 2002-07-30 Neurocrine Biosciences Inc Imidazo- y pirrolo [1,2-a]pirimid-4-onas como antagonistas receptores de la hormona liberadora de gonadotropina.
CA2309395A1 (en) * 1999-06-04 2000-12-04 Richard Lloyd Bowen Methods for preventing and treating alzheimer's disease
CA2386942A1 (en) 1999-10-15 2001-04-26 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
EP1393747A1 (en) 2000-04-13 2004-03-03 Takeda Chemical Industries, Ltd. Preventives/remedies for alzheimer's disease
CN1186326C (zh) 2000-07-05 2005-01-26 山之内制药株式会社 丙-1,3-二酮衍生物

Also Published As

Publication number Publication date
CA2444876A1 (en) 2002-12-27
IL156777A0 (en) 2004-02-08
SK14512003A3 (sk) 2004-08-03
CN1317030C (zh) 2007-05-23
ES2307760T3 (es) 2008-12-01
HK1072000A1 (en) 2005-08-12
KR20040000446A (ko) 2004-01-03
PL362319A1 (en) 2004-10-18
NO20034322L (no) 2003-09-26
UA80679C2 (en) 2007-10-25
BG108339A (bg) 2004-11-30
CN1575185A (zh) 2005-02-02
ATE400287T1 (de) 2008-07-15
EP1392348B1 (en) 2008-07-09
JP2004529207A (ja) 2004-09-24
NZ544417A (en) 2008-03-28
MXPA03008666A (es) 2004-10-15
US7288517B2 (en) 2007-10-30
PT1392348E (pt) 2008-09-09
AU2002310788B2 (en) 2007-04-05
SI1392348T1 (sl) 2008-12-31
US20020177556A1 (en) 2002-11-28
RU2003134949A (ru) 2005-02-10
EP1392348A1 (en) 2004-03-03
DK1392348T3 (da) 2008-09-29
NO20034322D0 (no) 2003-09-26
DE60227507D1 (de) 2008-08-21
WO2002102401A1 (en) 2002-12-27
ZA200305326B (en) 2003-07-30
RU2319501C2 (ru) 2008-03-20
HUP0400067A2 (hu) 2004-04-28
CZ20033167A3 (cs) 2004-08-18

Similar Documents

Publication Publication Date Title
BR0209290A (pt) Tratamento de demência e doenças neurodegenerativas com doses intermediárias de antagonistas de lhrh
NO20071560L (no) Vasopressin v1a-antagonister.
GB0129260D0 (en) Pharmaceutical compositions and their uses
LU92854I2 (fr) Combinaison de rilpivirine ou une forme thérapeutique équivalente qui en dérive telle que protégé par le brevet de base, tel qu'un sel pharmaceutiquement acceptable de rilpivirine, incluant le sel chlorhydrate de rilpivirine, et ténofovir, en particulier le fumarate de ténofovir disoproxil
GB0108592D0 (en) Therapeutic agents
AU2002302255A1 (en) Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
BR0307998A (pt) Hidroxietilaminas substituìdas
BR9408063A (pt) Antagonistas de receptores de taquicinina que nÆo sÆo pept¡deos
EP1613368A4 (en) Carboxamide-spiro hydantoin-CGRP Receptor Antagonists
EA200600971A1 (ru) Применение замещённых 2 - аминотетралинов для профилактического лечения болезни паркинсона
MA28106A1 (fr) Compositions immunogenes
BR0206495A (pt) Tratamento de distúrbios de cns empregando antagonistas de oxidase de d-aminoácido e oxidase de d-aspartato
BR0110383A (pt) Peptìdeo modulador de receptor de trombopoietina
MXPA04003298A (es) Compuestos de piperidina como antagonistas muscarinicos.
BR0213684A (pt) Uso de antagonistas do receptor de endotelina para o tratamento de doenças tumorìgenas
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
MY134019A (en) Aryl oxime-piperazines useful as ccr5 antagonists
BR9811821A (pt) 2-acilaminopropanaminas como antagonistas de receptores de taquicinina
MXPA04001986A (es) Composiciones y metodos para el tratamiento de enfermedades relacionadas a la inmunidad.
ZA200700945B (en) Derivatives of 1-phenylalkanecarboxylic acids for the treatment of neurodegenerative diseases
BR0211223A (pt) Derivados de 4-aminociclohexanol substituìdos
ATA8192003A (de) Verwendung von oxicam-verbindungen
PL425832A1 (pl) Genisteina oraz jej kompozycja do zastosowania w leczeniu choroby Alzheimera
WO2003100433A3 (en) Diagnostics and therapeutics for diseases associated with arginine vasopressin receptor 3 (avpr3)
WO2003090771A3 (en) Diagnostics and therapeutics for diseases associated with trace amine receptor 3(ta3)

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 7A. E 8A. ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2060 DE 29/06/2010.